目的 观察甜梦口服液联合草酸艾司西酞普兰治疗抑郁症的临床疗效。方法 选取2014年1月-2015年12月在天津市滨海新区塘沽安定医院就诊的抑郁症患者126例，随机分为对照组和治疗组，每组各63例。对照组患者口服草酸艾司西酞普兰片，10~20 mg/d。治疗组在对照组的基础上口服甜梦口服液，40 mL/d。两组患者均连续治疗8周。比较两组患者治疗前后临床疗效、HAMD评分和睡眠质量变化。结果 治疗后，对照组和治疗组痊愈率分别为55.5%和68.2%，两组比较差异具有统计学意义（P<0.05）。治疗2、4、8周后，两组患者HAMD评分均明显下降，同组治疗前后比较差异具有统计学意义（P<0.05）。且治疗2周后治疗组HAMD评分比对照组明显降低，两组比较差异具有统计学意义（P<0.05）。治疗后，对照组睡眠质量改善总有效率为87.3%，显著低于治疗组的93.6%，两组睡眠质量改善总有效率比较差异具有统计学意义（P<0.05）。结论 甜梦口服液联合草酸艾司西酞普兰能够改善抑郁症患者的睡眠质量，降低不良反应，提高患者的生活质量。

Objective To observe the clinical efficacy of Tianmeng Oral Liquid combined with escitalopram oxalate in treatment of depression. Methods Patients (126 cases) with depression in Tanggu Anding Hospital of Tianjin Binhai New Area from January 2014 to December 2015 were randomly divided into the control and treatment groups, and each group had 63 cases. The patients in the control group were po administered with Escitalopram Oxalate Tablets, 10-20 mg/d. The patients in the treatment group were po administered with Tianmeng Oral Liquid on the basis of the control group, 40 mL/d. The patients in two groups were treated for 8 weeks. After treatment, the changes of clinical efficacies, HAMD scores, and sleep quality in two groups were compared. Results After treatment, the cure rate in the control and treatment groups were 55.5% and 68.2%, respectively, and there were differences between two groups (P<0.05). After treatment for 2, 4, and 8 weeks, HAMD scores in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And after treatment for 2 weeks, HAMD scores in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, the sleep quality improving rate in the control group was 87.3%, which was significantly lower than that in the treatment group (93.6%), with significant difference between two groups (P<0.05). Conclusion Tianmeng Oral Liquid combined with escitalopram oxalate can improve sleep quality and quality of life with lower adverse reaction incidence.